Nordic Issuing

Ongoing case

QuiaPEG Pharmaceuticals Holding AB

Back to all cases

QuiaPEG Pharmaceuticals Holding AB

29 Nov - 15 Dec 2021Warrent redemption

The company develops patented technologies for the release of already approved or clinically validated drugs based on pegylation to improve the properties of biological drugs. Peglyceration has long been used to modify biological drugs. Normally, drugs are pegylated in such a way that the PEG molecule and the drug are permanently linked. This can lead to disadvantages, for example reduced effect in that the PEG molecule can block the binding of the drug to its target molecule (receptor). To avoid this, QuiaPEG has developed a technology that enables a gradual release of the drug, which retains the benefits of peglyceration while maintaining the full effect of the drug.

Read more on the company's website


The offer in summary

Subscription period:: 29 November- 15 December 2021

Price per share:: 0.50 SEK

Trading with warrant:: Until 13 December 2021

Settledate: : 15 December 2021

Marketplace:: Nasdaq First North Growth Market

Documents

  AML

Disclaimer

Due to restrictions in applicable law in the United States, Canace, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.